Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-21
    E.g., 2018-09-21

Archive Search

3 results
11:09 AM, Jan 18, 2017  |  BC Innovations | Distillery Techniques

Biomarkers

TECHNOLOGY: Plasma markers Serum ANG2 levels could help predict responses to anti- CTLA4 or anti- PD-1 …
the anti-PD-1 mAb Keytruda pembrolizumab or the anti-PD-1 mAb Opdivo nivolumab, high pretreatment levels of ANG2
in serum were associated with low overall survival post-treatment. Also in the patients, post-treatment serum ANG2
12:00 AM, Jul 14, 2011  |  BC Innovations | Distillery Techniques

Technology: Drug platforms

they selectively interacted with each other. That method enabled the production of a modified anti-VEGF, anti-angiopoietin 2
ANG2; ANGPT2) bispecific antibody that had better efficacy than a control antibody in a mouse model …
12:00 AM, Jan 06, 2011  |  BC Innovations | Distillery Techniques

Technology: Drug platforms

bispecific CovX-Body dubbed CVX-241 had low nanomolar binding affinity for its two targets: VEGF and angiopoietin 2
ANG2; ANGPT2). In three tumor xenograft mouse models of cancer, CVX-241 decreased tumor growth compared with …
monospecific CovX-Bodies targeting only VEGF or ANG2. CVX-241 (PF-05057459) from Pfizer Inc.'s CovX Research LLC unit …